Table 1.

Incidence of RAS mutations and patient characteristics

Age	Sex	Mutation	FAB/WHO classification	Cytogenetic studies	Clinical course
AML cohort (incidence, %)
N-Ras G12 (4.3)
83 y	F	G12D	M5B	46, XX	Initial diagnosis, deceased in induction
6 y	F	G12D	M1	46XX	n/a
20 y	M	G12D	AML, NOS	46, XY	n/a
10 mo	F	G12D	AML, NOS	failure	n/a
61 y	M	G12D	M1	n/a	Initial diagnosis, no f/u
14 y	F	G12D	M2	46, XX, add(6)(q?21), add(16)(q?22), add(17)(q?21), add(18)(q?21)45, X,t(X;1)(p11.2; p32), del(3)(p2/2),der(5)t(5;14)(p15;11.2), add(6)(q?22), del(10)(q?23), del(11)(p?14), −15, add(16)(q10), add(17)(q?21),−18, add(20)(q?11.2), +mar46, XX	Outside specimen for flow cytometry at diagnosis, BMT, relapse at 1 y, no additional f/u
35 y	F	G12D	M4	n/a	Outside specimen for flow cytometry at diagnosis, no additional f/u
48 y	M	G12D	M4	n/a	n/a
30 y	F	G12D	M5	n/a	Outside specimen for flow cytometry at diagnosis, no additional f/u
59 y	M	G12D	M1	n/a	Relapse at 1 y after induction therapy, no additional f/u
24 y	F	G12D	M5	n/a	Outside specimen for flow cytometry at diagnosis, no additional f/u
n/a	M	G12S	relapse M2	t(8;21)	n/a
67 y	F	G12A	M0	n/a	Outside specimen for flow cytometry at diagnosis, no additional f/u
n/a	M	G12V	AML, NOS	n/a	Outside specimen for flow cytometry at diagnosis, no additional f/u
N-Ras G13 (0.6)
n/a	n/a	G13D	AML, NOS	n/a	n/a
35 y	M	G13R	M1	n/a	Outside specimen for flow cytometry at diagnosis, no additional f/u
N-Ras Q61 (1.8)
22 y	F	Q61R	M4	46, XX	Initial diagnosis, relapse at 6 mo, no f/u
n/a	n/a	Q61R	M5	n/a	n/a
n/a	M	Q61R	M5	n/a	Outside specimen for flow cytometry at diagnosis, BMT, remission at day 110, no additional f/u
37 y	M	Q61K	M5	46, XY	n/a
n/a	M	Q61K	M5	n/a	n/a
n/a	M	Q61H	M5	n/a	Relapse sample, no f/u
N-Ras G60 (0.3)
n/a	M	G60E	AMLL	n/a	n/a
K-Ras G12 (1.5)
51 y	F	G12D	M4Eo	46, XX, inv(16)	Initial diagnosis, remission, no f/u
n/a	n/a	G12D	M4	n/a	n/a
n/a	F	G12D	M2	n/a	n/a
9 y	F	G12D	RAEB-T	n/a	BMT, relapse at 1 y after induction therapy, no additional f/u
79 y	F	G12A	M2	Normal	n/a
K-Ras G13 (0.6)
n/a	n/a	G13D	AML, NOS	n/a	n/a
67 y	F	G13D	M0	n/a	Outside specimen for flow cytometry at diagnosis, no additional f/u
K-Ras V14 (0.3)
70 y	F	V14I	M1	very complex 44, −5, add13p, add14q, −17, +22	n/a
K-Ras A146 (0.6)
63 y	F	A146T	AML, NOS	46XX del 5q11q32	Initial diagnosis, complete remission at 14 mo, no f/u
23 y	F	A146T	M1	46, XX, −1, inv(3)(q?21q?27), del(5)(q?13q31), add(5)(p?12), add(7)(p11), −10, add(10)(p?13), add(11)(q13), del(12)(p11), der(15)t(/1;15)(p?22; q2?4), add(16)(q?22), −18, +marAll 22	Outside specimen for flow cytometry at diagnosis, relapse at 1 y after induction therapy, BMT w/ immediate relapse, no additional f/u
Other canonical (2.7)*
n/a	n/a	G12, G13, Q61	AML, NOS	n/a	n/a
n/a	n/a	G12, G13, Q61	AML, NOS	n/a	n/a
n/a	n/a	G12, G13, Q61	AML, NOS	n/a	n/a
n/a	n/a	G12, G13, Q61	AML, NOS	n/a	n/a
n/a	n/a	G12, G13, Q61	AML, NOS	n/a	n/a
n/a	n/a	G12, G13, Q61	AML, NOS	n/a	n/a
n/a	n/a	G12, G13, Q61	AML, NOS	n/a	n/a
n/a	n/a	G12, G13, Q61	AML, NOS	n/a	n/a
n/a	n/a	G12, G13, Q61	AML, NOS	n/a	n/a
CMML cohort (incidence, %)
N-Ras G12 (9.4)
72	M	G12D	CMML	46, XY[20]	n/a
65	M	G12D	CMML	46, XY[20]	n/a
80	M	G12D	CMML	BCR-ABL–negative (FISH)	n/a
K-Ras G12 (6.3)
n/a	F	G12D	aCML	BCR-ABL–negative (FISH)	n/a
53	M	G12A	CMML	46, XY[20]	n/a
K-Ras G13 (3.1)
65	M	G13D	CMML	NA	n/a
K-Ras T74 (3.1)
n/a	F	T74P	aCML	BCR-ABL–negative (FISH)	n/a
K-Ras A146 (6.3)
71	M	A146T	CMML	n/a	n/a
48	M	A146T	CMML	n/a	n/a

The estimated proportion of mutant allele is given in parentheses after the mutation type.

aCML indicates atypical chronic myelogenous leukemia; AML, acute myeloid leukemia; F, female; M, male; n/a, not available; BMT, bone marrow transplantation; and RAEB, refractory anemia with excess blasts.

^*Known canonical mutation, but patient data unavailable.